Bio-Techne Corporation
TECHHealthcareNASDAQBiotechnology · Last scanned Jul 17, 2026
Scan Results
Daily timeframePart of the healthcare sector, Bio-Techne Corporation (TECH) is listed under Biotechnology. With a market capitalization of $11.18B, it sits in large-cap territory. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Market Cap
$11.18B
Beta
1.29
P/E (TTM)
102.53
P/E (Fwd)
35.09
EPS (TTM)
$0.70
EPS (Fwd)
$2.05
ROE
5.3%
ROA
7.4%
Cash
$214.1M
Total Debt
$290.3M
Free CF
$299.8M
52W Change
34.7%
Annual Financials
Cash vs Debt
Bio-Techne Corporation carries $290.3M in total debt against $214.1M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $299.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 5.3%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 7.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $1.11B to $1.22B.
At over 50x earnings, TECH carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bio-Techne Corporation and its sector.